Cohort flow through Medication-Assisted Treatment — retention, attrition & overdose outcomes
Every patient who starts Medication-Assisted Treatment (MAT) — buprenorphine, methadone, or extended-release naltrexone — enters as part of a cohort with equal footing on day one. But induction onto medication is not the outcome that determines survival. In addiction medicine, the single strongest predictor of reduced overdose death, reduced illicit opioid use, and improved social functioning is time spent in continuous treatment: retention, not initiation.
For decades, addiction treatment metrics emphasized "successful induction" — did the patient start medication. But induction says almost nothing about survival. Opioid use disorder (OUD) is a chronic relapsing condition; a single week of medication exposure barely dents the trajectory of the disease. What the epidemiological literature consistently shows is a dose-response relationship between time-in-treatment and every downstream outcome that matters: mortality, illicit use, criminal justice involvement, employment, and housing stability.
Cohort studies following patients on buprenorphine or methadone find that each additional month of continuous retention reduces the hazard of fatal overdose, and that the protective effect largely disappears within weeks of discontinuation — tolerance drops, but craving and triggers do not. This is why "days retained" has become the primary outcome metric in modern OUD treatment research, displacing older single-point measures like "abstinence at 30 days."
A patient retained in MAT for 12 months has a fraction of the overdose mortality risk of a patient who dropped out at 60 days — even though both technically "received treatment." Retention duration is the active ingredient.
• Methadone: a full opioid agonist, dispensed daily under observation at licensed Opioid Treatment Programs (OTPs). Strong retention evidence (often the highest of the three) but daily-visit requirements are themselves an access barrier for patients with jobs, childcare, or transportation limits.
• Buprenorphine: a partial agonist with a ceiling effect, prescribable in office-based settings (including via telehealth since pandemic-era rule changes). Lower overdose risk if taken outside supervision, and materially more flexible dosing — but historically gated by prescriber waiver requirements and pharmacy stocking issues.
• Naltrexone (extended-release): an opioid antagonist requiring full detoxification before starting, dosed monthly by injection. No misuse potential, but induction barriers are highest (patients must be fully opioid-free first) and missed doses instantly remove protection with no residual agonist buffer — retention tends to be the most fragile of the three.
This simulator models a cohort of patients entering MAT together and tracks what happens to each one over the treatment timeline: who stays, who drops, when, and why. Two levers dominate real-world retention curves — psychosocial support intensity (counseling, case management, peer recovery coaching) and access barrier level (dosing convenience, transportation, prior-authorization friction, mandatory counseling attendance as a condition of medication access). Adjust them to see how the same starting cohort produces very different 12-month outcomes.
Across nearly every MAT retention study, the sharpest drop in the survival curve happens in the first 30 to 90 days. This "cliff" is not random noise — it reflects a predictable convergence of dosing friction, unmanaged side effects, unresolved psychosocial instability, and the simple fact that early sobriety is the period of highest craving and lowest coping-skill development.
Multiple overlapping risk factors concentrate in the first 90 days:
• Dosing friction: daily observed dosing (methadone) or frequent office visits (buprenorphine induction) collide with unstable jobs, lack of transportation, or long clinic travel distances — missing a handful of doses is often enough to trigger disengagement.
• Side effects and induction discomfort: precipitated withdrawal risk during buprenorphine induction, constipation and sedation on methadone, or post-acute withdrawal syndrome generally, all peak early before patients or prescribers have optimized dosing.
• Untreated psychiatric comorbidity: co-occurring depression, anxiety, PTSD, or other substance use disorders are common in OUD populations and, if unaddressed, drive early dropout independent of the medication itself.
• Housing instability and stigma: patients without stable housing face major logistical and psychological barriers to consistent clinic attendance; internalized or externalized stigma around "still being on drugs" (a common misconception about agonist medication) discourages continued engagement.
The 90-day mark functions as a de facto triage point in the literature: patients who make it past 90 days retained have dramatically better odds of remaining in care at 12 months than patients who are still in the first 90 days — small early interventions have outsized long-run leverage.
Retention curves for MAT are not linear decay — they resemble a steep early drop followed by a long, much flatter tail. This has direct implications: interventions concentrated in the first 90 days (rapid follow-up after missed doses, same-day access to re-induction, proactive outreach) have far higher marginal value per dollar than interventions targeting stable, already-retained patients at month 8. Programs that specifically instrument the early window — text-message check-ins, peer navigators contacting patients within 24–48 hours of a missed dose, low-barrier walk-in re-entry — measurably flatten the cliff.
In this stage, the cohort dots crossing the early portion of the treatment river peel off at a rate driven by the Access Barrier and Support Intensity sliders — high barrier + low support produces a steep, early cliff; low barrier + high support flattens the curve dramatically, keeping far more of the cohort on the main path into the stabilization stages.
Medication alone treats the neurobiology of opioid dependence — receptor occupancy, withdrawal suppression, craving reduction — but it does not resolve the psychosocial conditions that often triggered or sustained use in the first place. The evidence base for combining medication with counseling, case management, and peer support is one of the most consistent findings in the addiction treatment literature.
"Psychosocial support" in MAT is not one intervention but a bundle:
• Individual and group counseling: cognitive-behavioral and motivational approaches that build coping skills for cravings and relapse triggers.
• Case management: practical, logistical support — helping patients navigate insurance, transportation, housing applications, and employment services, removing the everyday frictions that otherwise cause missed doses and disengagement.
• Peer recovery coaching: support from individuals with lived experience of recovery, shown to improve engagement and reduce stigma-driven avoidance of care.
• Contingency management: structured incentives (vouchers, prizes) for verified abstinence or attendance, one of the most robust evidence-based add-ons in the addiction treatment toolkit.
Importantly, none of these substitute for medication — the evidence is clear that medication is the necessary foundation. But layered together, they measurably increase the fraction of a cohort that survives the early cliff and reaches stabilization.
A key nuance: mandating counseling as a precondition for receiving medication (rather than offering it as a voluntary, low-barrier add-on) tends to reduce overall retention — patients who cannot or will not immediately engage with intensive counseling are turned away from the medication that would have protected them regardless.
A recurring theme in the literature is the sharp contrast between coercive/mandated treatment models (e.g., criminal-justice-mandated attendance, drug-court-linked medication access, involuntary commitment) and voluntary, patient-centered engagement models. Coerced cohorts often show inflated short-term "compliance" that collapses immediately once external mandate pressure is removed — retention after release from supervision drops sharply. Voluntary engagement models, especially those built on low-barrier access and harm-reduction principles (meeting patients where they are, not requiring abstinence from other substances as a precondition), consistently show higher durable retention because the patient's own motivation, not external enforcement, sustains attendance.
The Psychosocial Support Intensity slider governs the frequency and strength of support-service "pulses" applied to the retained cohort in this stage. Higher support intensity reduces the probability of dropout for patients who are still on the treatment path, and modestly reduces illicit-use rates and overdose risk downstream — reflecting the additive but not replacement role support services play alongside medication.
For patients who remain retained past the early attrition window, the 3-to-12-month period is where the protective effects of MAT compound. Craving intensity declines, opioid receptor occupancy from agonist medication stabilizes tolerance and blocks the euphoric effect of illicit use, and behavioral routines around dosing, work, and daily life re-form.
Opioid agonist medications (methadone, buprenorphine) work by occupying mu-opioid receptors at a stable, sustained level, which does two things simultaneously: it suppresses withdrawal and craving, and — critically — it creates cross-tolerance that blunts the euphoric "high" from illicit opioid use on top of the medication. This pharmacological blockade effect strengthens behaviorally over months as patients experience fewer rewarding illicit-use episodes, weakening the learned association between use and reward.
Behaviorally, stabilization is reinforced by re-establishing routine: reliable dosing schedules, reduced time spent obtaining illicit drugs, and — for many patients — the beginning of reintegration into employment, family relationships, and stable housing. Each of these functions as its own protective factor, creating a positive feedback loop that further reduces relapse risk the longer a patient stays retained.
Illicit opioid use among retained patients typically falls by well over half within the first six months of continuous treatment — the "risk halo" shrinks fastest during exactly this window, which is why interventions that get patients past 90 days pay compounding dividends.
It is important not to over-idealize this stage: dropout does not stop after 90 days, it merely slows. Life disruptions — job loss, relationship breakdown, incarceration, involuntary dose tapering by a prescriber, insurance lapses — can still knock a stabilized patient off treatment at any point in the 3–12 month window. Because these patients had built up months of reduced illicit use and increased physiological stability, an unexpected dropout during this phase can carry a disproportionately high overdose risk: tolerance has often dropped just as much as during initial abstinence, but external circumstances (isolation, unfamiliarity with current supply potency, fentanyl contamination) remain unchanged or worse.
In this stage, each retained patient dot in the animation carries a shrinking translucent "risk halo" — visually representing declining relapse and overdose probability as time-in-treatment accumulates. The halo shrinks faster under higher psychosocial support intensity, reflecting the literature's finding that wraparound services accelerate, not just enable, physiological and behavioral stabilization.
The clearest way to see why retention is the outcome measure that matters in addiction medicine is to place the retained and dropped-out branches of the same starting cohort side by side. Same patients, same starting conditions — but wildly divergent trajectories in overdose risk, illicit use days, and functional stability, driven almost entirely by whether they stayed in treatment.
This stage splits the cohort into two visual lanes: patients who remained in continuous MAT and patients who dropped out at some point along the timeline. The dropped-out lane shows a materially higher frequency of overdose-flash events, reflecting the well-documented spike in fatal and non-fatal overdose risk in the weeks immediately following treatment discontinuation — a period where tolerance has often dropped but drug-seeking behavior and exposure to an increasingly fentanyl-contaminated illicit supply have not.
The retained lane, by contrast, shows a cohort with substantially reduced illicit use days, fewer overdose events, and improving proxies for functional stability (employment engagement, stable housing) that compound the longer retention continues.
This is the central policy insight of MAT outcomes research: interventions should be judged not by whether they get a patient onto medication, but by whether they keep the patient on medication. A treatment system optimized purely for induction rates can look successful on paper while producing worse population-level overdose outcomes than one optimized for retention.
Historically, buprenorphine prescribing in the US required clinicians to complete a special DATA-2000 waiver ("X-waiver") with patient-count caps, and many state Medicaid programs imposed prior-authorization requirements or mandatory concurrent-counseling requirements before covering the medication. Research consistently associated these access barriers with lower population-level retention and treatment initiation — patients who might have started or stayed on buprenorphine were filtered out by administrative friction unrelated to clinical need.
The 2023 elimination of the federal X-waiver requirement (part of the Consolidated Appropriations Act) and parallel efforts to reduce prior-authorization and mandatory-counseling requirements were directly motivated by this evidence: removing friction between a patient wanting treatment and a patient receiving treatment measurably improves retention, because retention — not access alone — is what saves lives.
Synthesizing the evidence base across all five stages of this model:
• Flexible, low-barrier dosing (take-home doses, telehealth, extended-release formulations) reduces the daily friction that drives early dropout.
• Voluntary, integrated psychosocial support — offered alongside, not as a precondition for, medication — improves retention without gatekeeping access.
• Rapid re-engagement after a missed dose or lapse (rather than automatic discharge from a program) prevents a single missed appointment from becoming a permanent dropout.
• Harm-reduction-oriented, non-punitive program design outperforms coercive or abstinence-mandated models on durable, voluntary retention.
• Policy-level barrier removal (ending prior authorization, ending waiver/cap requirements, expanding telehealth prescribing) shifts population-level retention curves upward, which is the single highest-leverage lever available to reduce opioid overdose mortality at scale.